What is Solid Biosciences?
Solid Biosciences is a life sciences enterprise dedicated to the development of transformative gene therapies for rare neuromuscular and cardiac diseases. The company's core pipeline includes SGT-003 for Duchenne muscular dystrophy, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and AVB-401 for BAG3-mediated dilated cardiomyopathy. By integrating advanced technology with deep disease-management expertise, Solid Biosciences operates at the intersection of scientific discovery and patient-centric care. Its market position is defined by a commitment to addressing the underlying causes of fatal cardiac and neuromuscular conditions, effectively bridging the gap between laboratory innovation and clinical application.
How much funding has Solid Biosciences raised?
Solid Biosciences has raised a total of $455M across 3 funding rounds:
Stock Offering
$125M
Share Placement
$90M
Stock/Share Issuance
$240M
Stock Issuance/Offering (2018): $125M, investors not publicly disclosed
Share Placement (2020): $90M led by EcoR1 Capital, Aspire Capital Fund, RA Capital Management, Bain Capital, Perceptive Advisors, Suvretta Capital Management, Ikarian Capital, and Boxer Capital
Stock/Share Issuance (2026): $240M, investors not publicly disclosed
Key Investors in Solid Biosciences
EcoR1 Capital
EcoR1 Capital is a San Francisco-based investment fund focused on the biotech sector, aiming to build long-term partnerships with innovative entrepreneurs dedicated to advancing therapeutic innovation.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing their TechAtlas think tank to support strategic decisions.
Bain Capital
Bain Capital is a leading global private investment firm that applies deep sector expertise and broad capabilities to provide flexible capital solutions tailored to the specific needs of high-growth companies.
What's next for Solid Biosciences?
With the recent influx of capital, Solid Biosciences is well-positioned to advance its clinical-stage assets and expand its research capabilities. The strategic focus will likely center on the successful execution of ongoing trials and the potential expansion of its therapeutic portfolio. As the company transitions into a more mature phase of its lifecycle, the emphasis will shift toward regulatory engagement and the scaling of manufacturing processes to support future commercialization. Investors will be closely monitoring the data readouts from its lead programs, which serve as the primary catalysts for long-term value creation in the competitive gene therapy landscape.
See full Solid Biosciences company page
